

FORM FOR ADVANCE VOTING

The form must be received by Isofol Medical AB (publ) no later than May 13, 2022.

The shareholder below is hereby exercising the voting right for all of the shareholder's shares in Isofol Medical AB (publ), Reg. No. 556759-8064 at the annual general meeting held on May 19, 2022. The voting right is exercised in accordance with the voting options marked below.

Shareholder	Personal identity number/registration number

Assurance (if the undersigned is a legal representative of a shareholder who is a legal entity): I, the undersigned, am a board member, the CEO or a signatory of the shareholder and solemnly declare that I am authorised to submit this advance vote on behalf of the shareholder and that the contents of the advance vote correspond to the shareholder's decisions.

Assurance (if the undersigned represents the shareholder by proxy): The undersigned solemnly declare that the enclosed power of attorney corresponds to the original and has not been revoked.

Place and date	
Signature	
Clarification of signature	
Telephone number	E-mail

Instructions:

- Complete all the requested information above
- Select the preferred voting options below
- Print, sign and send the form by post to Isofol Medical AB (publ), "Annual general meeting 2022", Att. Gustaf Albèrt, Arvid Wallgrens backe 20, SE-413 46 Gothenburg, Sweden, or via e-mail to arsstamma@isofolmedical.com.
- If the shareholder is a natural person who is personally voting in advance, it is the shareholder who should sign under Signature above. If the advance vote is submitted by a proxy of the shareholder, it is the proxy who should sign. If the advance vote is

submitted by a legal representative of a legal entity, it is the representative who should sign

- If the shareholder votes by proxy, a proxy shall be enclosed to the form. If the shareholder is a legal entity, a certificate of incorporation or an equivalent certificate of authority should be enclosed to the form

A shareholder whose shares have been registered in the name of a bank or securities institute must register its shares in its own name to vote. Instructions for this is included in the notice convening the general meeting.

A shareholder cannot give any other instructions than selecting one of the options specified at each point in the form. If a shareholder wishes to abstain from voting in relation to a matter, kindly refrain from selecting an option. A vote (i.e. the advance voting in its entirety) is invalid if the shareholder has provided the form with specific instructions or conditions or if pre-printed text is amended or supplemented.

The advance voting form, together with any enclosed authorisation documentation, shall be provided to Isofol Medical AB (publ) no later than May 13, 2022. An advance vote can be withdrawn up to and including May 13, 2022 by contacting Isofol Medical AB (publ) via e-mail to arsstamma@isofolmedical.com.

One form per shareholder will be considered. If more than one form is submitted, the form with the latest date will be considered. The form latest received by Isofol Medical AB (publ) will be considered if two forms are dated at the same date. An incomplete or wrongfully completed form may be discarded without being considered. If a shareholder has voted in advance and attends the general meeting in person or through a proxy, the advance vote is still valid except to the extent the shareholder casts votes during the general meeting or otherwise withdraws its casted advance vote. If the shareholder chooses to participate in a voting during the general meeting, the submitted advance vote will be replaced by the vote cast at the general meeting.

Note that the advance vote does not constitute a notification to participate in the general meeting at the venue in person or through proxy. Instructions for shareholders who wish to participate in the general meeting at the venue in person or represented by a proxy are included in the notice convening the meeting.

For the complete proposals, kindly refer to the notice convening the general meeting and the company's website.

For information on how your personal data is processed, see the integrity policy that is available at Euroclear's website, www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf.

Annual general meeting in Isofol Medical AB (publ) held on May 19, 2022

The options below comprise the submitted proposals included in the notice convening the general meeting and are held available on the company's website.

2. Election of chairman of the annual general meeting
Yes <input type="checkbox"/> No <input type="checkbox"/>
4. Approval of the agenda
Yes <input type="checkbox"/> No <input type="checkbox"/>
6. Determination of whether the annual general meeting has been duly convened
Yes <input type="checkbox"/> No <input type="checkbox"/>
8. Resolution regarding adoption of the income statement and the balance sheet and, if applicable, the consolidated income statement and the consolidated balance sheet
Yes <input type="checkbox"/> No <input type="checkbox"/>
9. Resolution regarding allocations of the company's result pursuant to the adopted balance sheet
Yes <input type="checkbox"/> No <input type="checkbox"/>
10. Resolution regarding discharge from liability of the board members and the CEO
a. Pär-Ola Mannefred, Chairman of the board
Yes <input type="checkbox"/> No <input type="checkbox"/>
b. Magnus Björsne, Board member
Yes <input type="checkbox"/> No <input type="checkbox"/>
c. Robert Marchesani, Board member
Yes <input type="checkbox"/> No <input type="checkbox"/>
d. Lennart Jeansson, Board member
Yes <input type="checkbox"/> No <input type="checkbox"/>
e. Anna Belfrage, Board member
Yes <input type="checkbox"/> No <input type="checkbox"/>
f. Alain Herrera, Board member
Yes <input type="checkbox"/> No <input type="checkbox"/>
g. Aram Mangasarian, Board member
Yes <input type="checkbox"/> No <input type="checkbox"/>

<p>h. Paula Boulton, Board member</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>i. Ulf Jungnelius, CEO</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>11. Resolution regarding the number of board members, deputy board members, auditors and deputy auditors</p>
<p>a. Number of board members and deputy board members</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>b. Number of auditors and deputy auditors</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>12. Resolution regarding the fees to the board of directors and the auditors</p>
<p>a. Fees to the board of directors</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>b. Fees to the auditors</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>13. Election of board members and auditor</p>
<p>a. Magnus Björnsne, Board member (Re-election)</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>b. Robert Marchesani, Board member (Re-election)</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>c. Lennart Jeansson, Board member (Re-election)</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>d. Anna Belfrage, Board member (Re-election)</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>e. Alain Herrera, Board member (Re-election)</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>f. Aram Mangasarian, Board member (Re-election)</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>g. Paula Boulton, Board member (Re-election)</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>h. Jan Törnell, Board member (Election)</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>

<p>i. Jan Törnell, Chairman of the board (Election)</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>j. KPMG AB, Auditor (Re-election)</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>14. Determination of procedure for appointment of the nomination committee</p>
<p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>15. Presentation of the remuneration report for approval</p>
<p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>16. Resolution on adoption of guidelines for executive remuneration</p>
<p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>17. The board of directors' proposal to change the articles of association</p>
<p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>18. The board of directors' proposal regarding authorisation for the board of directors to resolve on new issues</p>
<p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>